http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112451531-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-62 |
| filingDate | 2020-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112451531-B |
| titleOfInvention | Aspirin and rivaroxaban compound preparation and preparation method thereof |
| abstract | The invention discloses an aspirin and rivaroxaban compound medicinal preparation and a preparation method thereof. The compound preparation is prepared by filling aspirin micro-tablets and rivaroxaban micro-tablets into capsules. The aspirin is in enteric-coated release, the rivaroxaban is in sustained-release, and the rivaroxaban is used for treating related diseases such as thrombolysis and thrombosis prevention, the aspirin micro-tablets are enteric-coated tablets, the specification of the aspirin micro-tablets is 25-100 mg/tablet, 1-4 tablets are filled in each capsule, the specification of the rivaroxaban sustained-release micro-tablets is 1.25-20 mg/tablet, and 1-8 tablets are filled in each capsule. The compound solid preparation of the invention is prepared by filling different medicines and different types of micro-tablets into the same capsule, is convenient for patients to take and reduces the risk of missed taking. Moreover, the capsule is convenient to open, and the micro-tablet filled capsule has a more flexible medicine taking mode. |
| priorityDate | 2020-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.